Tech Company Financing Transactions
Proteon Therapeutics Funding Round
Private investors participated in a $4.3 million capital raise for Proteon Therapeutics. The funding round was announced by the company on 2/19/2014.
Transaction Overview
Company Name
Announced On
2/19/2014
Transaction Type
Debt
Venture Equity
Venture Equity
Amount
$4,338,660
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed. SEC regulatory filing. Contact technology company for investment details, if applicable. Not an offer or solicitation for sale of securities.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
200 West St.
Waltham, MA 02451
USA
Waltham, MA 02451
USA
Phone
Website
Email Address
Overview
Proteon Therapeutics (NASDAQ: PRTO) is a biopharmaceutical company developing PRT-201, a novel human recombinant protein that permanently dilates segments of blood vessels, blocks vasospasm, and reduces the formation of vascular scarring.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Timothy Noyes
Chief Financial Officer
George Eldridge
Chief Medical Officer
Steven Burke
VP - Bus. Development
Daniel Gottlieb
VP - General Counsel
Matthew Kowalsky
VP - Manufacturing
John Najim
VP - Marketing
Scott Toner
VP - R & D
Pamela Gustafson
Browse more venture capital transactions:
Prev: 2/19/2014: Trumaker venture capital transaction
Next: 2/19/2014: GuestDriven venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on funding rounds that are announced publicly. All VC database entries reported here come from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs